Home > En > CU64 a promising radionucleide for immuno-PET imaging

CU64 a promising radionucleide for immuno-PET imaging

Wednesday 27 November 2013

Copper-64 can be used for immuno-PET imaging

In the November issue of the Journal of Nuclear Medicine a Japanese paper from the National Cancer Centre Hospital in Tokyo reports on the results of a clinical study in a limited number of 6 patients using anti-HER2 trastuzumab Mab labeled with copper-64 for visualization of primary or metastatic breast cancer with PET imaging (Tamura K et al, J Nucl Med 2013 ; 54 : 1869-1875).
Forty eight hours after injection of a moderate activity of copper-64 ( 130 MBq or 3 mCi) primary and metastatic tumor sites have been clearly visualized and a dosimetric study allowed to evaluate dose delivered to normal tissues.